Page last updated: 2024-12-08

4-aminobenzoylglutamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-aminobenzoylglutamic acid: RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-(4-aminobenzoyl)-L-glutamic acid : A dipeptide resulting from the formal condensation of the carboxylic acid group of 4-aminobenzoic acid with the amino group of L-glutamic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID196473
CHEMBL ID3278332
CHEBI ID61114
SCHEMBL ID63083
MeSH IDM0057684

Synonyms (60)

Synonym
CHEBI:61114 ,
4-aminobenzoylglutamic acid
p-aminobenzoyl-l-glutamic acid
l-n-(p-aminobenzoyl)glutamic acid
n-(p-aminobenzoyl)glutamic acid
4271-30-1
l-glutamic acid, n-(4-aminobenzoyl)-
p-aminobenzoylglutamic acid
nsc-71042
n-(4-aminobenzoyl)-l-glutamic acid
n-(p-aminobenzoyl)-l-glutamic acid
n-(4-aminobenzoyl)-l-glutamic acid, >=98% (tlc)
4-aminobenzoylglutamate
A-5000
A0442
(2s)-2-[(4-aminobenzoyl)amino]pentanedioic acid
einecs 224-261-7
glutamic acid, n-(p-aminobenzoyl)-, l-
unii-9bky99a8hj
9bky99a8hj ,
n-(p-aminobenzoyl)glutamic acid (van)
n-4-aminobenzoyl-l-glutamic acid
nsc 71042
(s)-2-(4-aminobenzamido)pentanedioic acid
A825991
AKOS010366208
AM20060626
AKOS015855631
calcium folinate impurity a [ep impurity]
(4-aminobenzoyl)-l-glutamic acid
4-aminobenzoylglutamic acid [usp-rs]
4-aminobenzoylglutamic acid [dsc]
(p-aminobenzoyl)-l-glutamic acid
folic acid hydrate impurity a [ep impurity]
(-)-n-(p-aminobenzoyl)glutamic acid
aminobenzoyl-l-glutamic acid, p-
methotrexate impurity k [ep impurity]
n-(4-aminobenzoyl)-l-glutamic acid [mi]
(2s)-2((4-aminobenzoyl)amino)pentanedioic acid
CHEMBL3278332 ,
SCHEMBL63083
n-(4-aminobenzene-1-carbonyl)-l-glutamic acid
mfcd00042821
(2s)-2-[(4-aminophenyl)formamido]pentanedioic acid
4-aminobenzoylglutamic acid, united states pharmacopeia (usp) reference standard
folic acid impurity a, european pharmacopoeia (ep) reference standard
n-(4-aminobenzoyl)-l-glutamic acid (folic acid imp a), pharmaceutical secondary standard; certified reference material
532-63-8
DTXSID10873641
folic acid impurity a
p-amino benzamide glutamic acid
DS-15609
Q27130821
BCP15199
h-4-abz-glu-oh
(2s)-2-[(4-aminobenzoyl)amino]pentanedioic acid (n-(4-aminobenzoyl)-l-glutamic acid)
CS-W012429
bdbm50542900
4-aminobenzoyl-l-glutamic acid
HY-W011713

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Dual-label stable isotope dilution assays for the simultaneous quantification of isotopologic folates in clinical samples offer the perspective for differentiating between unlabeled folates from endogenous body pools and administered [13C5]-labeled folates from a test dose when performing bioavailability trials."( Quantification of isotope-labeled and unlabeled folates and folate catabolites in urine samples by stable isotope dilution assay.
Büttner, BE; Köhler, P; Ohrvik, VE; Rychlik, M; Witthöft, CM, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" The method was sensitive enough to detect pABG in plasma generally and unmetabolized folic acid in the plasma of a volunteer after oral dosage of an aqueous folic acid solution."( Quantitation of folates and their catabolites in blood plasma, erythrocytes, and urine by stable isotope dilution assays.
Mönch, S; Netzel, G; Netzel, M; Rychlik, M, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
substituted aniline
N-acyl-L-alpha-amino acidAny L-alpha-amino acid carrying an N-acyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)Ki180.00000.00000.37564.9000AID1660990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1660990Inhibition of human DHFR in presence of DHF and NADPH by UV-vis spectrometry by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID1146770Competitive inhibition of Escherichia coli B H2-pteroate synthetase assessed as decrease in H2-pteroate formation using [7-14C]-PABA as substrate treated with enzyme for 10 mins prior to substrate challenge for 40 mins by radioassay method1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
P-Aminobenzoic acid derivatives as inhibitors of the cell-free H2-pteroate synthesizing system of Escherichia coli.
AID1146773Competitive inhibition of Escherichia coli B H2-pteroate synthetase assessed as decrease in H2-pteroate formation using [7-14C]-PABA as substrate treated with enzyme for 10 mins prior to substrate challenge for 40 mins by Dixon plot analysis1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
P-Aminobenzoic acid derivatives as inhibitors of the cell-free H2-pteroate synthesizing system of Escherichia coli.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (28.07)18.7374
1990's19 (33.33)18.2507
2000's15 (26.32)29.6817
2010's5 (8.77)24.3611
2020's2 (3.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.20 (24.57)
Research Supply Index4.14 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (6.90%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]